Received Feb 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | — | — |
Twinrix late third dose; Twinrix late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too short in a 52-year-old female patient who received HAB (Twinrix) for prophylaxis. Co-suspect products included HAB (Twinrix) for prophylaxis. On 20-FEB-2025, the patient received the 3rd dose of Twinrix. On 19-FEB-2025, the patient received the 2nd dose of Twinrix. On 19-FEB-2025, not applicable after receiving Twinrix and an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Twinrix late second dose). On 20-FEB-2025, the patient experienced drug dose administration interval too short (Verbatim: Twinrix late third dose). The outcome of the drug dose administration interval too short and drug dose administration interval too long were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 20-FEB-2025 Other HCP reported that she could give a third dose of Twinrix to a patient who received the second dose on 19th February 2025 and the first dose six months ago. Third dose has not been given. Patient received 2nd dose of Twinrix,?later than the recommended interval, which led to lengthening of vaccinations schedule. (Drug dose administration interval too long) Patient received 3rd dose of Twinrix,?earlier than the recommended interval, which led to shortening of vaccinations schedule. (Drug dose administration interval too short)